<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17498" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Anabolic Steroid Use Disorder</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>AlShareef</surname>
            <given-names>Sanad</given-names>
          </name>
          <aff>PCOM/Cape Fear Valley Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gokarakonda</surname>
            <given-names>Srinivasa B.</given-names>
          </name>
          <aff>University of Arkansas For Medical Sciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Marwaha</surname>
            <given-names>Raman</given-names>
          </name>
          <aff>Case Western Reserve Un/MetroHealth MC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sanad AlShareef declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Srinivasa Gokarakonda declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Raman Marwaha declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17498.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Androgen use has become a major public health concern due to the transition of use of androgens from strictly sports to a much wider spectrum of the population. Anabolic-androgenic steroids (AAS) are steroidal androgens which include natural androgens such as male sex hormone testosterone or could be synthetic to mimic the action of the endogenous male hormone. Some people misuse anabolic steroids for various reasons. For example, athletes abuse anabolic steroids to enhance performance and prolong endurance. Non-athletic people misuse anabolic steroids to increase body weight and lean muscle mass without increasing fat mass in the body. The potential side effects of anabolic steroid abuse are significant, and health care providers should be aware of patients at risk of anabolic-androgenic steroid misuse. This activity describes the evaluation and management of anabolic steroid use disorder and highlights the role of the interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the at-risk patient populations for anabolic steroid use disorder.</p></list-item><list-item><p>Review the legitimate medical uses for anabolic steroid therapy.</p></list-item><list-item><p>Outline the treatment and management options available for patients exhibiting signs of anabolic steroid misuse disorder.</p></list-item><list-item><p>Explain the importance of improving care coordination among the interprofessional team to enhance the delivery of care for patients presenting with anabolic steroid misuse disorder.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17498&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17498">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17498.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The term "anabolic" means the use of body energy to promote growth and regulate constructive metabolism.&#x000a0;Anabolic-androgenic steroids (AAS) are steroidal androgens, which include natural androgens such as male sex hormone testosterone or could be synthetic to mimic the action of the endogenous male hormone. Androgen use has become a major public health concern due to the transition of the use of androgens from strictly sports to&#x000a0;a much wider spectrum of the population.&#x000a0;The lifetime prevalence of anabolic-androgenic steroid (AAS) use worldwide is estimated to be 1% to 5%<xref ref-type="bibr" rid="article-17498.r1">[1]</xref>. Due to their abuse potential, the Anabolic Steroid Control Act of 2004 amended the Controlled Substances Act to redefine anabolic steroids to "any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone) sets forth a list of substances included as anabolic steroids, including tetrahydrogestrinone (THG), androstenedione, and specified related chemicals". Testosterone and its analogs are placed in DEA Schedule III.&#x000a0;</p>
        <p>Androgens stimulate and precipitate the development of male sex characteristics. Anabolic steroids and androgens are medically prescribed (orally or injectable) to treat hormonal imbalance for hypogonadism, impotence in men, delayed puberty in adolescent boys. For&#x000a0;women, they can be used to treat breast cancer, endometriosis, osteoporosis, and muscle loss in patients with cancer or HIV. Misuse or abuse is commonly seen in athletes to enhance performance and prolong endurance. Non-athletes misuse anabolic steroids to increase their body weight and lean muscle mass without increasing the body's fat mass.<xref ref-type="bibr" rid="article-17498.r2">[2]</xref><xref ref-type="bibr" rid="article-17498.r3">[3]</xref><xref ref-type="bibr" rid="article-17498.r4">[4]</xref><xref ref-type="bibr" rid="article-17498.r5">[5]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-17498.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Approximately 3 to 4 million Americans used anabolic-androgenic steroids to increase muscle mass, whether for sports to increase their performance or cosmetic purposes, such as enhancing their appearance. People who have misused steroids may be suffering from muscle dysmorphia, which is a behavioral syndrome. AAS are frequently used by fighters, bouncers, and security personnel to enhance their appearance and job performance.&#x000a0;The popular term used for the anabolic steroids is &#x0201c;steroids,&#x0201d; and other common names are "roids," "juice," "andro," "gear," and "stackers."&#x000a0;</p>
      </sec>
      <sec id="article-17498.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The prevalence of AAS abuse has steadily increased over the last two decades.<xref ref-type="bibr" rid="article-17498.r6">[6]</xref>&#x000a0;Due to the increasing prevalence, the potential health hazards of anabolic steroids are also rising.&#x000a0;A meta-analysis of 187 studies demonstrated that being athletic and/or male were significant predictors of AAS abuse<xref ref-type="bibr" rid="article-17498.r7">[7]</xref>. The prevalence&#x000a0;in males is 6.4%, compared to 1.6% in females.<xref ref-type="bibr" rid="article-17498.r7">[7]</xref> According to NIDA(2018), anabolic steroid misuse is predominately seen in male weightlifters in their 20s or 30s. According to the 2019 NIDA-funded Monitoring the Future study, steroid use continues to be a concern among high school students. A&#x000a0;study in Germany showed that 48.1% of&#x000a0;AAS abusers, who frequented fitness centers, received their supply from healthcare providers.<xref ref-type="bibr" rid="article-17498.r8">[8]</xref><xref ref-type="bibr" rid="article-17498.r9">[9]</xref> In a 2006 survey of 500&#x000a0;AAS users, 78.4% were nonathletic and non-competitive bodybuilders.<xref ref-type="bibr" rid="article-17498.r10">[10]</xref><xref ref-type="bibr" rid="article-17498.r11">[11]</xref> &#x000a0;The method of choice for administration for the majority of AAS users (99.2%) was self-administrable injections.<xref ref-type="bibr" rid="article-17498.r7">[7]</xref> Of concern was that as high as 13% reported unsafe practices for injecting the steroids, such as sharing needles, reusing needles, and sharing vials.<xref ref-type="bibr" rid="article-17498.r12">[12]</xref></p>
      </sec>
      <sec id="article-17498.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Among AAS users, about&#x000a0;30% develop dependence, which is characterized by chronic AAS use despite negative consequences and adverse effects on physical, psychosocial, or occupational functioning.<xref ref-type="bibr" rid="article-17498.r13">[13]</xref>&#x000a0;According to a model on AAS dependence, in stage 1, which is referred to as "myoactive" phase, high-dose AAS are used with dietary and rigorous weight training. Stage 2 is characterized by the chronic and high amounts of AAS use leading to the brain reward development, contributing to abuse and dependence.<xref ref-type="bibr" rid="article-17498.r14">[14]</xref>&#x000a0;Internet and social media have thrown enormous challenges to the day to day lives and practices of the modern world.&#x000a0; The dissemination of misinformation via these mediums, combined with the lack of restrictions on AAS lead to dangerous practices by young athletes.<xref ref-type="bibr" rid="article-17498.r15">[15]</xref>&#x000a0;&#x000a0;</p>
        <p>Hypogonadism is a hallmark of AAS abuse, which may have profound effects on the reproductive system. The majority of AAS users found to have low gonadotropin and testosterone levels even after the discontinuation of AAS.<xref ref-type="bibr" rid="article-17498.r16">[16]</xref>&#x000a0;Administration of exogenous AAS results in down-regulation of the HPA axis leading to reduced endogenous production of testosterone by suppressing&#x000a0;the normal testicular function (reduced testicular volume, sperm, and testosterone production)<xref ref-type="bibr" rid="article-17498.r1">[1]</xref>.&#x000a0; In a retrospective study, 21% of 382 men with hypogonadism receiving testosterone treatment reported taking exogenous androgens. For men who have a&#x000a0;history of taking androgens and then stopping them, the sperm count returns to normal after approximately four months to a year. Older men would take a longer time to recover than younger men after discontinuation. Androgen intake may lead to low sperm count, small testes, high hemoglobin and hematocrit values, low serum to non-detectable serum LH, and low sex hormone-binding globulin. These findings should raise the suspicion of exogenous androgen intake in men competing in sports.<xref ref-type="bibr" rid="article-17498.r7">[7]</xref>&#x000a0;</p>
        <p>Cardiovascular risk of AAS includes myocardial dysfunction, coronary atherosclerosis<xref ref-type="bibr" rid="article-17498.r17">[17]</xref>; hypercoagulopathy and hepatic dysfunction<xref ref-type="bibr" rid="article-17498.r18">[18]</xref>, hypertension, life-threatening arrhythmia, and sudden death.<xref ref-type="bibr" rid="article-17498.r19">[19]</xref>&#x000a0;Concentric Left ventricular hypertrophy is commonly seen in long term steroid users even after discontinuation of AAS.<xref ref-type="bibr" rid="article-17498.r20">[20]</xref>&#x000a0;Prolonged use of AAS will also lead to elevation of LDL and reduction of HDL, conferring an increased risk of the cardiac event.<xref ref-type="bibr" rid="article-17498.r19">[19]</xref>&#x000a0;AAS abuse may also lead to psychiatric and behavioral disturbances.<xref ref-type="bibr" rid="article-17498.r18">[18]</xref>&#x000a0;According to an observational study by Christoffersen<bold>&#x000a0;</bold>et al, there is increased aggression, violent behaviors, and a 9 fold increased risk of crime and imprisonment in people with AAS abuse.<xref ref-type="bibr" rid="article-17498.r21">[21]</xref>&#x000a0;The long term complications of AAS intake by females include hirsutism, acne, temporal male-pattern hair recession, deepening of the voice, and clitoromegaly.<xref ref-type="bibr" rid="article-17498.r1">[1]</xref>&#x000a0;Some women will experience oligomenorrhea or even amenorrhea, as well as breast atrophy.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-17498.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A comprehensive history and physical examination are needed to diagnose AAS abuse. The clinician may suspect AAS abuse in the following situations:</p>
        <list list-type="bullet">
          <list-item>
            <p>Child or adolescent who is experiencing early development of secondary sexual characteristics, decrease in height, and premature closure of epiphyses</p>
          </list-item>
          <list-item>
            <p>Females experiencing temporal hair recession, hirsutism, acne, irregular menses, breast atrophy, deepening of the voice (irreversible), clitoromegaly, decrease in total body fat and increase in muscle mass<xref ref-type="bibr" rid="article-17498.r16">[16]</xref>.</p>
          </list-item>
          <list-item>
            <p>Males exhibiting rapid increased in muscle mass and strength and experiencing changes such as gynecomastia, small testes, low sperm count, impotence, and acne<xref ref-type="bibr" rid="article-17498.r1">[1]</xref><xref ref-type="bibr" rid="article-17498.r16">[16]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17498.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Exogenous administration of androgens should be suspected in a patient who is in a competitive sport or activity, who demonstrates behavioral changes such as aggression, depression, or irritability, or&#x000a0;with blood work changes such as deficient luteinizing hormone (LH) concentration, high hematocrit, and low sex hormone-binding globulin (SHBG).<xref ref-type="bibr" rid="article-17498.r22">[22]</xref>&#x000a0;Gynecomastia in males and Hirsutism in females may be further investigated to rule out AAS use<xref ref-type="bibr" rid="article-17498.r1">[1]</xref>.</p>
      </sec>
      <sec id="article-17498.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>According to the current evidence, the most effective treatment for AAS is the discontinuation of AAS use, treatment of withdrawal symptoms, a combination of behavioral therapy, and symptomatic treatments. Treatment of AAS is based on the duration of use, the likelihood of withdrawal symptoms, treatment goals of the patient, and risk-benefit analysis of the treatments.&#x000a0;Anawalt(2019) discusses four management strategies for AAS;1. Cessation with no medical therapy; 2. Cessation and initiation of clomiphene therapy; 3.&#x000a0;Cessation and initiation of&#x000a0;hCG therapy; 4. Conversion of nonprescription AASs to prescription testosterone<xref ref-type="bibr" rid="article-17498.r1">[1]</xref>.</p>
        <p>In AAS users with less than one year of use, testosterone levels normalize to baseline within 6 months of discontinuation<xref ref-type="bibr" rid="article-17498.r1">[1]</xref>. However, in chronic users, prolonged duration of hypogonadism and low testosterone is observed<xref ref-type="bibr" rid="article-17498.r23">[23]</xref><xref ref-type="bibr" rid="article-17498.r24">[24]</xref><xref ref-type="bibr" rid="article-17498.r23">[23]</xref>.&#x000a0;Restoration of hormonal balance is important to prevent hypogonadism. In athletes, androgen use must be discontinued immediately, even though withdrawal symptoms are expected. If initiating testosterone replacement therapy for the treatment of hypogonadism, therapeutic use exemptions from appropriate agencies should be sought before initiation of replacement therapies.<xref ref-type="bibr" rid="article-17498.r1">[1]</xref>. Clomiphene or hCG therapy may be considered for men with chronic high dose AAS use<xref ref-type="bibr" rid="article-17498.r1">[1]</xref>.&#x000a0;Providers should also address other behavioral and mental health comorbidities concurrently.&#x000a0; Anxiety and depression should be treated with antidepressants and cognitive-behavioral therapies.&#x000a0;In patients with conduct disorder and other substance use disorders, appropriate behavioral interventions along with appropriate referrals are warranted<xref ref-type="bibr" rid="article-17498.r1">[1]</xref><xref ref-type="bibr" rid="article-17498.r25">[25]</xref>.&#x000a0;</p>
      </sec>
      <sec id="article-17498.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Clinicians should investigate the use of anabolic-androgenic steroids in middle-aged males and young men who present with gynecomastia, hirsutism, coronary artery disease (CAD) and left ventricular dysfunction.<xref ref-type="bibr" rid="article-17498.r26">[26]</xref><xref ref-type="bibr" rid="article-17498.r1">[1]</xref><xref ref-type="bibr" rid="article-17498.r26">[26]</xref>&#x000a0;Additionally, healthcare providers should investigate comorbid mental health issues or substance use disorders.</p>
      </sec>
      <sec id="article-17498.s10" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>The common side effects of androgens include gynecomastia, shrinking of testicles, azoospermia, and infertility in men<xref ref-type="bibr" rid="article-17498.r16">[16]</xref>; and mood changes and aggression (&#x0201c;roid rage&#x0201d;), stunted height, and early puberty. Females with AAS abuse may have severe acne, menstrual irregularities, hirsutism, and clitoromegaly.<xref ref-type="bibr" rid="article-17498.r16">[16]</xref>&#x000a0;All groups can experience high blood pressure, changes in cholesterol, liver diseases such as cysts, heart diseases such as coronary artery disease, kidney diseases, and the risk of infections due to unsterile injections.<xref ref-type="bibr" rid="article-17498.r11">[11]</xref> In observational studies&#x000a0;on males who used&#x000a0;anabolic steroids, there&#x000a0;was also higher coronary plaque formation volume when compared to non-users. Moreover, approximately 71% of the anabolic steroid users had impaired ability to pump blood efficiently, leading to lower-than-normal left ventricle ejection fraction.<xref ref-type="bibr" rid="article-17498.r27">[27]</xref><xref ref-type="bibr" rid="article-17498.r28">[28]</xref></p>
      </sec>
      <sec id="article-17498.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Like with any substance with addictive potential, abrupt cessation of the AAS use leads to withdrawal symptoms including anxiety and depression.<xref ref-type="bibr" rid="article-17498.r1">[1]</xref>&#x000a0;Other withdrawal symptoms include fatigue, sleep problems, loss of appetite, decreased libido, and steroid cravings. Among the most serious withdrawal symptoms is depression, which could lead to suicidal ideation and suicide attempts. Studies have shown that patients who misuse steroids&#x000a0;may use other illicit drugs to help reduce side effects such as depression, anxiety, irritability, and lack of sleep.<xref ref-type="bibr" rid="article-17498.r29">[29]</xref><xref ref-type="bibr" rid="article-17498.r30">[30]</xref><xref ref-type="bibr" rid="article-17498.r31">[31]</xref></p>
      </sec>
      <sec id="article-17498.s12" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Androgen use complications include&#x000a0;cardiac hypertrophy, decreased serum HDL cholesterol, hypogonadism after discontinuing exogenous androgens, and neuropsychiatric concerns.<xref ref-type="bibr" rid="article-17498.r24">[24]</xref> Many studies show an&#x000a0;association between the nonmedical use of androgens and increases in risky and criminal behavior among the androgen intake abusers.<xref ref-type="bibr" rid="article-17498.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>In a survey of 10000 to 15000 college students, the use of androgens correlated highly with drinking and driving, cigarette smoking, illicit drug use, and alcohol misuse.<xref ref-type="bibr" rid="article-17498.r32">[32]</xref><xref ref-type="bibr" rid="article-17498.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>Anabolic steroids are completely prohibited in sports, whether in- or out-of-competition. The following organizations prohibit anabolic steroids intake: National Collegiate Athletic Association (NCAA), International Olympic Committee (IOC), U.S. Anti-Doping Agency (USADA), and World Anti-Doping Agency (WAD).&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17498.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>The potential side effects of anabolic steroid misuse are significant and chronic. Health care providers should be aware of patients at risk of anabolic-androgenic steroid misuse. Ongoing patient education about the potential side effects should be provided for patients who take androgens for therapeutic use. Timely identification of the anabolic steroid abuse and appropriate referral for treatment is highly warranted.&#x000a0;</p>
      </sec>
      <sec id="article-17498.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Clinicians should target treating depression, body-image, and dysmorphia and associated detrimental behavioral patterns&#x000a0;in groups at risk of anabolic-androgenic steroid misuse.</p>
      </sec>
      <sec id="article-17498.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17498&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17498">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/anabolic-steroid-use-disorder/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17498">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17498/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17498">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17498.s16">
        <title>References</title>
        <ref id="article-17498.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anawalt</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Management of Anabolic Androgenic Steroid Use.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2019</year>
            <month>Jul</month>
            <day>01</day>
            <volume>104</volume>
            <issue>7</issue>
            <fpage>2490</fpage>
            <page-range>2490-2500</page-range>
            <pub-id pub-id-type="pmid">30753550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Higgins</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Heshmat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Androgen abuse and increased cardiac risk.</article-title>
            <source>South Med J</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>105</volume>
            <issue>12</issue>
            <fpage>670</fpage>
            <page-range>670-4</page-range>
            <pub-id pub-id-type="pmid">23211503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Penning</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Veldstra</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Daamen</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Olivier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Verster</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Drugs of abuse, driving and traffic safety.</article-title>
            <source>Curr Drug Abuse Rev</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-32</page-range>
            <pub-id pub-id-type="pmid">20088818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dawson</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Drugs in sport - the role of the physician.</article-title>
            <source>J Endocrinol</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>170</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-61</page-range>
            <pub-id pub-id-type="pmid">11431137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaushik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sontineni</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular disease and androgens: a review.</article-title>
            <source>Int J Cardiol</source>
            <year>2010</year>
            <month>Jun</month>
            <day>25</day>
            <volume>142</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-14</page-range>
            <pub-id pub-id-type="pmid">19923015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graham</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Grace</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Kicman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Anabolic steroid use: patterns of use and detection of doping.</article-title>
            <source>Sports Med</source>
            <year>2008</year>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>505</fpage>
            <page-range>505-25</page-range>
            <pub-id pub-id-type="pmid">18489196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sagoe</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Molde</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Andreassen</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Torsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pallesen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis.</article-title>
            <source>Ann Epidemiol</source>
            <year>2014</year>
            <month>May</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>383</fpage>
            <page-range>383-98</page-range>
            <pub-id pub-id-type="pmid">24582699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alquraini</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Auchus</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Strategies that athletes use to avoid detection of androgenic-anabolic steroid doping and sanctions.</article-title>
            <source>Mol Cell Endocrinol</source>
            <year>2018</year>
            <month>Mar</month>
            <day>15</day>
            <volume>464</volume>
            <fpage>28</fpage>
            <page-range>28-33</page-range>
            <pub-id pub-id-type="pmid">28130115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iyer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Handelsman</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Androgens.</article-title>
            <source>Front Horm Res</source>
            <year>2016</year>
            <volume>47</volume>
            <fpage>82</fpage>
            <page-range>82-100</page-range>
            <pub-id pub-id-type="pmid">27347677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ip</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Barnett</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Tenerowicz</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>The Anabolic 500 survey: characteristics of male users versus nonusers of anabolic-androgenic steroids for strength training.</article-title>
            <source>Pharmacotherapy</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>8</issue>
            <fpage>757</fpage>
            <page-range>757-66</page-range>
            <pub-id pub-id-type="pmid">21923602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parkinson</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Anabolic androgenic steroids: a survey of 500 users.</article-title>
            <source>Med Sci Sports Exerc</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>644</fpage>
            <page-range>644-51</page-range>
            <pub-id pub-id-type="pmid">16679978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Givens</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Deuster</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Androgens and Androgen Derivatives: Science, Myths, and Theories: Explored From a Special Operations Perspective.</article-title>
            <source>J Spec Oper Med</source>
            <year>2015</year>
            <season>Fall</season>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>98</fpage>
            <page-range>98-104</page-range>
            <pub-id pub-id-type="pmid">26360363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanayama</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brower</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Pope</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>Anabolic-androgenic steroid dependence: an emerging disorder.</article-title>
            <source>Addiction</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>104</volume>
            <issue>12</issue>
            <fpage>1966</fpage>
            <page-range>1966-78</page-range>
            <pub-id pub-id-type="pmid">19922565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brower</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Anabolic steroid abuse and dependence.</article-title>
            <source>Curr Psychiatry Rep</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>377</fpage>
            <page-range>377-87</page-range>
            <pub-id pub-id-type="pmid">12230967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fink</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schoenfeld</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Hackney</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maekawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakazato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Horie</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Anabolic-androgenic steroids: procurement and administration practices of doping athletes.</article-title>
            <source>Phys Sportsmed</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-14</page-range>
            <pub-id pub-id-type="pmid">30247933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christou</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Christou</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Markozannes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tsatsoulis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mastorakos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tigas</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Effects of Anabolic Androgenic Steroids on the Reproductive System of Athletes and Recreational Users: A Systematic Review and Meta-Analysis.</article-title>
            <source>Sports Med</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>47</volume>
            <issue>9</issue>
            <fpage>1869</fpage>
            <page-range>1869-1883</page-range>
            <pub-id pub-id-type="pmid">28258581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baggish</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Kanayama</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Pope</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use.</article-title>
            <source>Circulation</source>
            <year>2017</year>
            <month>May</month>
            <day>23</day>
            <volume>135</volume>
            <issue>21</issue>
            <fpage>1991</fpage>
            <page-range>1991-2002</page-range>
            <pub-id pub-id-type="pmid">28533317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kam</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Yarrow</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Anabolic steroid abuse: physiological and anaesthetic considerations.</article-title>
            <source>Anaesthesia</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>60</volume>
            <issue>7</issue>
            <fpage>685</fpage>
            <page-range>685-92</page-range>
            <pub-id pub-id-type="pmid">15960720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vanberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Atar</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Androgenic anabolic steroid abuse and the cardiovascular system.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2010</year>
            <issue>195</issue>
            <fpage>411</fpage>
            <page-range>411-57</page-range>
            <pub-id pub-id-type="pmid">20020375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Urhausen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Albers</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kindermann</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Are the cardiac effects of anabolic steroid abuse in strength athletes reversible?</article-title>
            <source>Heart</source>
            <year>2004</year>
            <month>May</month>
            <volume>90</volume>
            <issue>5</issue>
            <fpage>496</fpage>
            <page-range>496-501</page-range>
            <pub-id pub-id-type="pmid">15084541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christoffersen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Dalhoff</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Horwitz</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Anabolic-androgenic steroids and the risk of imprisonment.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2019</year>
            <month>Oct</month>
            <day>01</day>
            <volume>203</volume>
            <fpage>92</fpage>
            <page-range>92-97</page-range>
            <pub-id pub-id-type="pmid">31421475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ip</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Barnett</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Tenerowicz</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Vo</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Psychological and physical impact of anabolic-androgenic steroid dependence.</article-title>
            <source>Pharmacotherapy</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>10</issue>
            <fpage>910</fpage>
            <page-range>910-9</page-range>
            <pub-id pub-id-type="pmid">23033230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanayama</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>DeLuca</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baggish</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bhasin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pope</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>Prolonged hypogonadism in males following withdrawal from anabolic-androgenic steroids: an under-recognized problem.</article-title>
            <source>Addiction</source>
            <year>2015</year>
            <month>May</month>
            <volume>110</volume>
            <issue>5</issue>
            <fpage>823</fpage>
            <page-range>823-31</page-range>
            <pub-id pub-id-type="pmid">25598171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rasmussen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Selmer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>&#x000d8;stergren</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Schou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gustafsson</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Faber</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Juul</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kistorp</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study.</article-title>
            <source>PLoS One</source>
            <year>2016</year>
            <volume>11</volume>
            <issue>8</issue>
            <fpage>e0161208</fpage>
            <pub-id pub-id-type="pmid">27532478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanayama</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pope</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Associations of anabolic-androgenic steroid use with other behavioral disorders: an analysis using directed acyclic graphs.</article-title>
            <source>Psychol Med</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>48</volume>
            <issue>15</issue>
            <fpage>2601</fpage>
            <page-range>2601-2608</page-range>
            <pub-id pub-id-type="pmid">29490719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ha</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Weinrauch</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Brensilver</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Non-ischemic Cardiomyopathy Secondary to Left Ventricular Hypertrophy due to Long-term Anabolic-androgenic Steroid Use in a Former Olympic Athlete.</article-title>
            <source>Cureus</source>
            <year>2018</year>
            <month>Sep</month>
            <day>17</day>
            <volume>10</volume>
            <issue>9</issue>
            <fpage>e3313</fpage>
            <pub-id pub-id-type="pmid">30473946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akbari</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Esmailidehaj</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Avarand</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shariati</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pourkhalili</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Ischemic Preconditioning Efficacy Following Anabolic Steroid Usage: A Clear Difference Between Sedentary and Exercise-Trained Rat Hearts.</article-title>
            <source>Cardiovasc Toxicol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>287</fpage>
            <page-range>287-296</page-range>
            <pub-id pub-id-type="pmid">30535662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chistiakov</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Myasoedova</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Melnichenko</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Grechko</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Orekhov</surname>
                <given-names>AN</given-names>
              </name>
            </person-group>
            <article-title>Role of androgens in cardiovascular pathology.</article-title>
            <source>Vasc Health Risk Manag</source>
            <year>2018</year>
            <volume>14</volume>
            <fpage>283</fpage>
            <page-range>283-290</page-range>
            <pub-id pub-id-type="pmid">30410343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vlad</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Hancu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Popescu</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Lungu</surname>
                <given-names>IA</given-names>
              </name>
            </person-group>
            <article-title>Doping in Sports, a Never-Ending Story?</article-title>
            <source>Adv Pharm Bull</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>529</fpage>
            <page-range>529-534</page-range>
            <pub-id pub-id-type="pmid">30607326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ganson</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Cadet</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Exploring Anabolic-Androgenic Steroid Use and Teen Dating Violence Among Adolescent Males.</article-title>
            <source>Subst Use Misuse</source>
            <year>2019</year>
            <volume>54</volume>
            <issue>5</issue>
            <fpage>779</fpage>
            <page-range>779-786</page-range>
            <pub-id pub-id-type="pmid">30572768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guzzoni</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Selistre-de-Ara&#x000fa;jo</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Marqueti</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Tendon Remodeling in Response to Resistance Training, Anabolic Androgenic Steroids and Aging.</article-title>
            <source>Cells</source>
            <year>2018</year>
            <month>Dec</month>
            <day>07</day>
            <volume>7</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">30544536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Collomp</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Buisson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gravisse</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Belgherbi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Labsy</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Do</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Gagey</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Dufay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vibarel-Rebot</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Audran</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effects of short-term DHEA intake on hormonal responses in young recreationally trained athletes: modulation by gender.</article-title>
            <source>Endocrine</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>59</volume>
            <issue>3</issue>
            <fpage>538</fpage>
            <page-range>538-546</page-range>
            <pub-id pub-id-type="pmid">29322301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17498.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fink</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schoenfeld</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Nakazato</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The role of hormones in muscle hypertrophy.</article-title>
            <source>Phys Sportsmed</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>129</fpage>
            <page-range>129-134</page-range>
            <pub-id pub-id-type="pmid">29172848</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
